Prescient Therapeutics Ltd (PTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Prescient Therapeutics Ltd (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013250
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the AKT pathway, that is used in the development of various cancers, including ovarian and breast cancer as well as hematologic cancers such as acute myeloid leukemia; PTX-100, a drug that is used to kill cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). It develops immunotherapeutic products based on its Co-X-Gene technology platform. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.

Prescient Therapeutics Ltd (PTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 10
Equity Offering 12
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 12
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 13
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 14
Virax Announces Private Placement Of Shares For US$2.7 Million 15
Virax Completes Private Placement Of Units 16
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 17
Virax Completes Rights Issue Of Common Stock For US$0.53 Million 18
Acquisition 19
Virax Acquires Pathway Oncology 19
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 20
Prescient Therapeutics Ltd – Key Competitors 21
Prescient Therapeutics Ltd – Key Employees 22
Prescient Therapeutics Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Jan 15, 2016: Steven Yatomi – Clarke Appointed CEO: Prescient Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prescient Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 10
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 12
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 13
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 14
Virax Announces Private Placement Of Shares For US$2.7 Million 15
Virax Completes Private Placement Of Units 16
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 17
Virax Completes Rights Issue Of Common Stock For US$0.53 Million 18
Virax Acquires Pathway Oncology 19
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 20
Prescient Therapeutics Ltd, Key Competitors 21
Prescient Therapeutics Ltd, Key Employees 22
Prescient Therapeutics Ltd, Subsidiaries 23

★海外企業調査レポート[Prescient Therapeutics Ltd (PTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Memorial Sloan Kettering Cancer Center:企業のM&A・事業提携・投資動向
    Memorial Sloan Kettering Cancer Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Memorial Sloan Kettering Cancer Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • CyberOptics Corp (CYBE):企業の財務・戦略的SWOT分析
    Summary CyberOptics Corp (CyberOptics) is a technology company that offers high precision 3D sensors. The company’s products include SMT inspection, semiconductor and MRS sensors. CyberOptics SMT inspection provides solder paste inspection systems, automated optical inspection systems, and software …
  • Claris Lifesciences Ltd (533288)-製薬・医療分野:企業M&A・提携分析
    Summary Claris Lifesciences Ltd (Claris) is a manufacturer of generic drugs and pharmaceutical products. The company offers generic drugs that are directly injected into the human body, which is mainly used in the treatment of critical illnesses. Its products are offered through various delivery sys …
  • I-O Data Device, Inc. (6916):企業の財務・戦略的SWOT分析
    I-O Data Device, Inc. (6916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Oncolix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncolix Inc (Oncolix) is a clinical stage biopharmaceutical company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor …
  • NVIDIA Corp (NVDA):企業の財務・戦略的SWOT分析
    NVIDIA Corp (NVDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • TerSera Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary TerSera Therapeutics LLC (TerSera Therapeutics) is a pharmaceutical company that develops of specialty pharmaceutical products. The company offers ergotamine tartrate sublingual tablets, goserelin acetate implant, zoladex, and zoladex la. It develops products in the therapeutic areas of alle …
  • Aridis Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aridis Pharmaceuticals Inc (Aridis) is a biopharmaceutical companythat focusses on development of novel, differentiated therapies for infectious diseases. The company’s pipeline product uses disruptive platform technology to discover potent human monoclonal antibodies from patients.Its propr …
  • Telephone and Data Systems, Inc.:企業の戦略・SWOT・財務情報
    Telephone and Data Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Telephone and Data Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Scatec Solar ASA (SSO)-エネルギー分野:企業M&A・提携分析
    Summary Scatec Solar ASA (Scatec Solar) is an integrated independent producer of solar power that develops, builds, owns and operates solar power plants. It conducts project origination and development, project financing, design and engineering, procurement and construction management, operation and …
  • HudBay Minerals Inc:企業のM&A・事業提携・投資動向
    HudBay Minerals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HudBay Minerals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Mosaic Brands Ltd (MOZ):企業の財務・戦略的SWOT分析
    Mosaic Brands Ltd (MOZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • TE Connectivity Ltd (TEL):電力:M&Aディール及び事業提携情報
    Summary TE Connectivity Ltd (TE Connectivity), formerly Tyco Electronics Ltd, is a technology company. It designs and manufactures connectivity and sensor solutions. The company offers connectors; sensors; relays; heat shrink tubing; wire and cable; antennas and circuit protection devices. Its solut …
  • Intuitive Surgical, Inc.:企業の戦略・SWOT・財務情報
    Intuitive Surgical, Inc. - Strategy, SWOT and Corporate Finance Report Summary Intuitive Surgical, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Rheonix Inc:企業の製品パイプライン分析2018
    Summary Rheonix Inc (Rheonix) is a medical equipment company that develops molecular diagnostic products. The company offers automated and integrated molecular testing device. It develops Rheonix CARD cartridge technology which penetrates molecular testing markets from diagnostics labs to applied ma …
  • IBC Solar AG:電力:M&Aディール及び事業提携情報
    Summary IBC Solar AG (IBC Solar), formerly IBC Solartechnik, is a solar energy company that provides photovoltaic and energy storage solutions and services. The company’s product range includes solar parks, self-consumption systems for commercial enterprises and private households, diesel hybrid sol …
  • Alliant Energy Corporation:企業の戦略・SWOT・財務分析
    Alliant Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliant Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • QEP Resources Inc (QEP):企業の財務・戦略的SWOT分析
    QEP Resources Inc (QEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Vital Therapies Inc (VTL):医療機器:M&Aディール及び事業提携情報
    Summary Vital Therapies Inc (Vital Therapies) is a biotechnology company that discovers, develops and commercialize cell-based therapies. The company’s product candidate includes ELAD system, a human-cell-based bio artificial liver treatment designed to allow the patient's own liver to regenerate or …
  • Hutchison 3G UK Limited:企業の戦略・SWOT・財務分析
    Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report Summary Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆